Hsu WT, Galm BP, Schrank G, et al. - Researchers undertook this population-based retrospective cohort analysis to determine if specific RAAS (renin-angiotensin-aldosterone system) inhibitors are related to decreased mortality in patients with sepsis. In this study, differences among patients using different RAAS inhibitors were controlled by employing multivariable propensity score–based regression. There were overall 52,727 patients who were hospitalized with sepsis, of those, 7,642 and 4,237 were prescribed an ACEI (angiotensin-converting enzyme inhibitor) and an ARB (angiotensin II receptor blocker), respectively. Reduced 30-day mortality and 90-day mortality was reported in relation to prior ACEI use vs nonuse, using propensity score–matched analyses. An improved 90-day survival related to prior ARB use was reported. For the prior use of ACEI/ARB, the pooled estimates collected from the meta-analysis was 0.71 (95% CI, 0.58–0.87). A substantially lower short-term death following sepsis was evident in those who were already established on RAAS inhibitor therapy when sepsis occurred.